December 7, 2017 / 11:19 AM / 11 days ago

Sage's depression drug succeeds in mid-stage study

Dec 7 (Reuters) - Sage Therapeutics Inc said on Thursday its drug to treat patients with moderate to severe depression met the main goal in a mid-stage study.

The 89-patient study testing the drug, SAGE-217, showed statistically significant reduction of depression symptoms, compared to a placebo. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Shounak Dasgupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below